Autologous skin grafting has been commonly used in clinics for decades to close large wounds, yet the cellular and molecular interactions between the wound bed and the graft that mediates the wound repair are not fully understood. The aim of this study was to better understand the molecular changes in the wound triggered by autologous and synthetic grafting. Defining the wound changes at the molecular level during grafting sets the basis to test other engineered skin grafts by design. In this study, a full-thickness skin graft (SKH-1 hairless) mouse model was established. An autologous full-thickness skin graft (FTSG) or an acellular fully synthetic Biodegradable Temporising Matrix (BTM) was grafted. The wound bed/grafts were analysed at histological, RNA, and protein levels during the inflammation (day 1), proliferation (day 5), and remodelling (day 21) phases of wound repair. The results showed that in this mouse model, similar to others, inflammatory marker levels, including Il-6, Cxcl-1, and Cxcl-5/6, were raised within a day post-wounding. Autologous grafting reduced the expression of these inflammatory markers. This was different from the wounds grafted with synthetic dermal grafts, in which Cxcl-1 and Cxcl-5/6 remained significantly high up to 21 days post-grafting. Autologous skin grafting reduced wound contraction compared to wounds that were left to spontaneously repair. Synthetic grafts contracted significantly more than FTSG by day 21. The observed wound contraction in synthetic grafts was most likely mediated at least partly by myofibroblasts. It is possible that high TGF-β1 levels in days 1–21 were the driving force behind myofibroblast abundance in synthetic grafts, although no evidence of TGF-β1-mediated Connective Tissue Growth Factor (CTGF) upregulation was observed.

The use of intraoperative computerised tomography (CT) to aid surgical management of facial fractures obviates the need for postoperative surgical scans, decreases return to theatre rates, and subsequently decreases overall hospital stay. This allows for better appreciation of a complex operative landscape in almost real time, and may become the gold standard of treatment. As with radiological investigations, decreasing radiation exposure of patients is a key goal. The aim of this study was to examine the effective radiation doses in patients undergoing surgical management of their facial fractures with the aid of a fixed-arm CT. This retrospective study was conducted on patients who underwent surgical fixation of their facial fractures within a hybrid surgical suite equipped with a fixed-arm cone beam CT (CBCT) from July 2023 to November 2024. The CBCT was used to assess adequacy of bony fixation. Data from imaging was collected to assess total effective radiation dose. Data from 30 random patients who underwent standard CT facial bones (CTFB) were collected as control. Data from 24 patients was collected. The majority were male (17/24, 70.8%) with an age range of 20–94 years. The average dose of the effective doses calculated in the CTFB cohort was 0.64 mSv (SD 0.05). This is a more-than-twenty-five-fold reduction in the average effective dose in the CBCT cohort, which was 0.025 mSv (SD 0.01). There was a statistically significant difference between the two cohorts with p < 0.0001 (95% CI 0.60–0.64). This study demonstrates that intraoperative CBCT delivers a significantly lower effective dose to patients compared with postoperative CTFB. Where facilities exist, CBCT offers a safer and more efficient alternative, with future work needed to assess staff dose, wait times, and cost impacts.